

Supramolecular Encapsulation of Small-Ultra Red Fluorescent Proteins in Virus-Like Nanoparticles for Non-Invasive In Vivo Imaging Agents

Fabian C. Herbert, Olivia Brohlin, Tyler Galbraith, Candace Benjamin, Cesar A. Reyes, Michael A. Luzuriaga, Arezoo Shahrivarkevishahi, Jeremiah J. Gassensmith

Submitted date: 02/04/2020 • Posted date: 03/04/2020

Licence: CC BY-NC-ND 4.0

Citation information: Herbert, Fabian C.; Brohlin, Olivia; Galbraith, Tyler; Benjamin, Candace; Reyes, Cesar A.; Luzuriaga, Michael A.; et al. (2020): Supramolecular Encapsulation of Small-Ultra Red Fluorescent Proteins in Virus-Like Nanoparticles for Non-Invasive In Vivo Imaging Agents. ChemRxiv. Preprint.

https://doi.org/10.26434/chemrxiv.12067851.v1

Icosahedral virus-like particles (VLPs) derived from bacteriophages Qβ and PP7 encapsulating small-ultra red fluorescent protein (smURFP) were produced using a versatile supramolecualr capsid dissassemble-reassemble approach. The generated fluorescent VLPs display identical structural properties to their non-fluorescent analogs. Encapsulated smURFP shows indistinguishable photochemical properties to its unencapsulated counterpart, exhibits outstanding stability towards pH, and produces bright in vitro images following phagocytosis by macrophages. In vivo imaging allows biodistribution to be imaged at different time points. Ex vivo imaging of intravenously administered encapsulated smURFP reveleas localization in the liver and kidneys after 2 h blood circulation and substantial elimination constructs as non-invasive in vivo imaging agents.

File list (2)

Preprint.pdf (8.68 MiB)	view on ChemRxiv • download file
graphical abstract.png (391.06 KiB)	view on ChemRxiv • download file

Supramolecular Encapsulation of Small-Ultra Red Fluorescent Proteins in Virus-Like Nanoparticles for Non-Invasive *In Vivo* Imaging Agents


Fabian C. Herbert,† Olivia R. Brohlin,† Tyler Galbraith,† Candace Benjamin,† Cesar A. Reyes,† Michael A. Luzuriaga,† Arezoo Shahrivarkevishahi,† and Jeremiah J. Gassensmith*,†,‡

†Department of Chemistry and Biochemistry, ‡Department of Bioengineering, The University of Texas at Dallas, 800 West Campbell Road, Richardson, TX 75080, USA

Supporting Information Placeholder

Abstract. Icosahedral virus-like particles (VLPs) derived from bacteriophages Qβ and PP7 encapsulating small-ultra red fluorescent protein (smURFP) were produced using a versatile supramolecual capsid dissassemble-reassemble approach. The generated fluorescent VLPs display identical structural properties to their non-fluorescent analogs. Encapsulated smURFP shows indistinguishable photochemical properties to its unencapsulated counterpart, exhibits outstanding stability towards pH, and produces bright in vitro images following phagocytosis by macrophages. *In vivo* imaging allows biodistribution to be imaged at different time points. *Ex vivo* imaging of intravenously administered encapsulated smURFP reveleas localization in the liver and kidneys after 2 h blood circulation and substantial elimination after 16 h of imaging highlighting the potential application of these constructs as non-invasive in vivo imaging agents.

Soft proteinaceous nanoparticles derived from the capsids of bacteriophages or plants have emerged as promising technologies¹ in imaging,²⁻³ drug delivery,⁴⁻⁷ and as non-infectious models in vaccine development.^{4,6,8-14} In particular, virus-like particles (VLPs) engineered nanostructures that self-assemble from individual coat proteins (CPs) of a virus—are structurally similar to their viral analogs but lack the genetic material needed for replication. 15 VLPs can be expressed in a scalable and straightforward fashion in a variety of systems including insect cells, mammalian cells, and bacteria. 16 Further, VLPs are characterized by polyvalency—they are high symmetry quaternary structures with functional handles that facilitate multiple orthogonal surface functionalizations. 17-22 This chemical flexibility, their biocompatibility, and biodegradability9 have allowed VLPs to serve as multivalent platforms for the conjugation of therapeutics, 23 pH cleavable groups, 624 and fluorescent dyes. 19, 25-28 This emerging utility has necessitated a straightforward way to visualize the VLP both in vivo and in vitro. The typical strategies to afford fluorescent VLPs for cell and animal imaging have involved bioconjugation of synthetic dyes, which can be expensive, will occupy valuable reactive residues on protein surfaces, and can alter their structure and antigenicity.²⁹ Non-covalent methods of dye conjugation are sparse, though several elegant method using genetically encoded protein-peptide interactions has produced a modular method to encapsulate green fluorescent protein (GFP) within the hollow capsid of viral nanoparticles. ³⁰⁻³¹ Here, we utilize a supramolecular strategy to capture a proteinaceous far-red fluorescent probe for the production of near-infrared fluorescent VLPs (Scheme 1).



Scheme 1. Representation of the disassembly-reassembly process used for synthesis of far-red fluorescent virus-like particles. A) Chimera crystal structure of native PP7. B) Isolated coat protein obtained after incubation of VLP in urea, dithiothreitol, and trishydrochloride. C) Far-red fluorescent VLP packed with smURFP.

Far-red fluorescent proteins (FPs) have become desirable platforms as *in vivo* imaging agents, offering new alternatives to dyes and metal nanoparticles for the advancement of real time imaging of tissue.³²⁻³⁴ These probe's spectral properties lay in an optical window free of interaction between incident light and predominant endogenous molecules such as water or hemoglobin, resulting in reduced autofluorescence and better tissue penetration. ³⁵ FPs with absorbance maxima around 650 nm can be excited with red lasers (Cy5) commonly found in confocal microscopes, fluorescence-

activated cell sorters, and flow cytometers making them ideal platforms for *in vitro* imaging.³⁵⁻³⁶ Recently, a far-red fluorescent protein was developed from the allophycocyanin α -subunit (APC α)³⁷-³⁸ called small-ultra red fluorescent protein (smURFP), which was genetically tuned to incorporate biliverdin (BV), a tetrapyrrolic bile pigment ubiquitous to mammalian cells.³⁹ As a result, smURFP displays excitation/emission maxima of 642/670 nm, matching the organic reporter group Cy5, making it compatible with filter sets on modern fluorescent microscopes and animal imaging stations. Other far-red/near-infrared (NIR) FPs have been engineered from bacterial phytochromes to incorporate BV but are typically less stable and have lower overall brightness. 40-41 smURFP is the brightest of proteins derived from allophycocyanin capable of imaging within the near-infrared tissue window, possessing both the highest extinction coefficient (180,000 M⁻¹cm⁻¹) and quantum yield (~18%).42 Indeed, this FP displays comparable brightness to enhanced green-fluorescent protein (eGFP) and at least two-fold brighter than most coral derived far-red fluorescent proteins. Unlike GFP, smURFP is not pH sensitive, 43 making it useful for live cell imaging where the probe may end up in an acidic organelle like an endosome or lysosome.

Engineered VLPs from the family Leviviridae—including bacteriophage Qβ, bacteriophage MS2, and pseudomonas phage seven (PP7)—have emerged as prototypical VLP nanotechnology platforms and are structurally similar. The "inner surface" of the coat protein has a positive charge, which binds to random RNA, in turn directing the formation of intact capsids during recombinant expression in E. coli. This positive charge has been exploited to allow disassembled MS2 phage coat proteins to reassembly around negatively charged cargo, typically with the aid of osmolytes.44-45 Given that the APC α subunit has an isoelectric point⁴⁶ of 4.64, we suspected smURFP would act as a template for the reassembly of other Leviviridae capsids at neutral pH. In this report, we show that a disassembly followed by templated reassembly approach permits the encapsulation of smURFP inside both QB and PP7 in good yield producing bright fluorescent complexes referred to as S@Qβ and S@PP7 respectively. The resulting far-red fluorescent VLPs are indistinguishable in size to non-fluorescent VLP analogs. Further, the supramolecular constructs display identical photochemical properties to native smURFP. Finally, we show both constructs to be effective non-invasive in vivo imaging agent when injected subcutaneously and intravenously.

Experimental Section

Materials and Chemicals

FBEssence, 2-methyl imidazole, potassium chloride, potassium phosphate monobasic, potassium phosphate dibasic, sodium phosphate monobasic, sodium phosphate dibasic, Dulbecco's Modified Eagle's Medium (6429), Tris base, tryptone, peptone, yeast extract, glycine, sodium dodecyl sulfate, Lowry modified reagent, and sodium chloride were purchased from Thermo Fisher Scientific (Waltham, MA, USA, Research Product International (Mt Prospect, IL, USA), Chem-Impex Int'l (Wood Dale, IL, USA), VWR (Radnor, PA, USA), and Sigma-Aldrich (St. Louis, MO, USA). All reagents were used with no additional purification.

Protocol for Expression of Qβ and PP7.

Expression and purification of VLPs were done following a reported procedure,⁴⁷ which is briefly described below. Both plasmids were kindly gifted by Prof. M.G. Finn from the Georgia Institute of Technology. Transformed single colonies of BL21 DE3 *E. coli* cells were incubated in 50 mL of SOB media supplemented with kanamycin (50 µg mL⁻¹) overnight at 37 °C and 210 rpm (5 ×g). Cells were amplified in 2 L of media at 37 °C until OD600

ranged between 0.7-0.9. Expression proceeded by induction with 1 mM of isopropyl β-D-1-thiogalactopyranoside (IPTG) for 12 h at 37 °C. Cells were harvested through centrifugation with a Fiberlite F10 rotor at 10,500 rpm (19,510 ×g) for 30 min at 4 °C. Cell lysis was done using a cell homogenizer. The resulting lysate was centrifuged using a Fiberlite F10 rotor at 10,500 rpm (19,510 ×g) for 60 min at 4 °C. The supernatant was extracted, and the protein precipitated using 2 M ammonium sulfate, performed in a rotisserie for 12 h at 4 °C. The precipitate was harvested by centrifugation with a Fiberlite F10 rotor at 10,500 rpm (19,510 ×g) for 60 min at 4 °C, and the protein pellet re-suspended in 20 mL of potassium phosphate buffer (1 M, pH 7.0). Membrane bound proteins and lipids were removed through organic extraction using equal volumes of n-butanol and chloroform. The aqueous layer containing the VLPs was purified through 10-40% sucrose gradients using a SW-28 rotor at 28,000 rpm $(87,808 \times g)$ for 8 h. The collected VLP fractions were pelleted by centrifugation using a Beckman Type Ti-45 rotor at 40,000 rpm (179,200 ×g) for 4 h and re-suspended in potassium phosphate buffer (1 M, pH 7.0).

Protocol for Expression of smURFP

pBad-smURFP-RBS-HO-1 was a gift from Erik Rodriguez & Roger Tsien (Addgene plasmid # 80341; RRID:Addgene 80341) and purified as described below. Starter cultures of E. coli BL21 cells harboring the plasmids were amplified in SOB media supplemented with 50 μg mL-1 ampicillin at 37 °C. Induction was performed at OD 0.7 with 1% L-arabinose for a minimum of 12 h. Cells were pelleted at 10,500 rpm (19,510 $\times g$) for 30 mins using a Sorvall LYNX 4000 centrifuge, resuspended in 1× PBS pH 8 and lysed using a Microfluidics M-110P Microfluidizer. Cells were again centrifuged at 10.500 rpm (19.510 ×g) for 1 h to remove cell debris. The supernatant was purified using an NGC Quest 10 FPLC equipped with a 5-mL Bio-Scale Profinity IMAC cartridge. The samples were loaded using 1× PBS pH 8, washed with 10 mM imidazole in $1\times$ PBS, pH 8 and eluted with 200 mM imidazole in $1\times$ PBS, pH 8. GFP or smURFP containing fractions were dialyzed against MilliQ water for 3 days and lyophilized using a Labconco Freezone 2.5 Lyophilizer. Dried GFP or smURFP was stored at

Protocol for Encapsulation of smURFP in VLPs.

"Native" VLPs (10 mg mL⁻¹) were incubated in a disassembly solution consisting of 10 mM dithiothreitol, 20 mM Tris-HCl, 6 M urea, and 50 mM NaCl for 5 h at 4 °C with moderate stirring. Coat proteins pertaining to disassembled VLPs were harvested by centrifugation using a Fiberlite F10 rotor at 10,500 rpm (19,510 ×g) for 30 min at 4 °C. The supernatant was dialyzed against 50 mM NaCl and 10 mM acetic acid for 12 h using a 3.5 kDa dialysis bag. Excess salts were removed from the coat proteins through a sephadex G-25 column, that had previously been equilibrated with potassium phosphate buffer (1 M, pH 7.0). The collected fraction was concentrated using a 10 kDa molecular-weight cutoff (MWCO) spin filter for 30 min at 4,300 rpm (2,071 ×g). Further, coat proteins were combined with a ten-fold molar excess of fluorescent protein in a 10 mL glass vial and stirred for 30 min at 4 °C. Using a 3.5 kDa dialysis bag, fluorescent VLPs were then assembled by incubating the coat proteins and FP in a reassembly buffer consisting of 50 mM NaCl, 20 mM Tris-HCl (pH 7.5) 4°C. For optimization of encapsulation efficiency, the reassembly buffer was changed every 12 h (2 L) for a total cycle of 48 h. Further, the fluorescent VLPs were incubated in a 7 mM solution of hydrogen peroxide for 1 h to promote cysteine oxidation and full encapsulation of smURFP within the capsid. It is noteworthy that cysteine oxidation played a crucial role in our disassembly-reassembly process because without treatment in hydrogen peroxide, the cargo would

leak out of both Q β or PP7 as observed by fast-protein liquid chromatography (FPLC). Excess salts were removed by passing the fluorescent VLPs through a 10 cm sephadex G-25 column that had previously been equilibrated with potassium phosphate buffer (1 M, pH 7.0). Every milliliter of VLP loaded into the column required ~2.5 mL of buffer to elute. Fully assembled fluorescent capsids were harvested through centrifugation using a 100 kDa MWCO spin filter 30 min at 4,300 rpm (2,071 ×g).

Fluorescent Virus-like Particle Characterization. Protein concentration was assessed through Lowry modified Assay (ThermoFisher Scientific) using bovine serum albumin as the internal standard. Homogeneity and purity of fluorescent VLPs was measured with TEM, SEC, and DLS. All fluorescent particles were icosahedral in shape, monodispersed in size, and eluted between 12-16 mL from a Superose-6 SEC column, using potassium phosphate buffer (1 M, pH 7.0) as the mobile phase, a flow rate of 0.5 mL min⁻¹, and absorbance measurements at 280/642 nm respectively. Dynamic light scattering dynamic radii were recorded using potassium phosphate buffer (1 M, pH 7.0) and a protein concentration of 0.1 mg mL⁻¹. Spectral properties of each fluorescent VLP were recorded using native smURFP as control. Average number of encapsulated smURFP within the VLPs was assessed through gel densitometry, normalizing the dimer bands for the VLPs to estimate the concentration of Qβ or PP7 present in solution. This was complemented with UV-Vis, in which long-wavelength absorption values at 642 nm were used to determine the concentration of smURFP present inside the VLP. From this analysis we found that each VLP contained ~ 3 smURFP proteins housed in the interior of the capsid.

Live Cell Imaging. RAW Macrophage 264.7 cells were cultured in Dulbecco's Modified Eagle Medium supplemented with 10% FBEssence and 1% Penicillin-Streptomycin. 5×10^5 cells were seeded onto glass bottom dishes 1 day prior to experiment. The cells were incubated with 200 nM of fluorescent VLPs for 4 h. The cells were washed $3 \times$ with HBSS, stained with 300 nM Hoescht 33442 dye for 10 mins at 37 °C in PBS, and washed again $3 \times$ with HBSS. The cells were kept in 1 mL of clean supplemented media for live cell imaging using an Olympus FV3000 RS Confocal microscope. Both the GFP and Cy5 lasers were used at the same power for imaging. The images from the individual filtersets were overlayed using ImageJ software. Z-stack 3D projections were also made with Image J.

Noninvasive fluorescence studies of smURFP@VLPs in vivo. The following experiment was approved by the UT Dallas IACUC committee under protocol #18-17. All mice were fed a non-fluorescent diet and shaved to remove autofluorescence of hair. Mice were separated into 4 groups (n=3) and injected either subcutaneously or intravenously (IV) with saline, smURFP (n), S@Q β , or S@PP7—the VLP-containing solutions were prepared to ensure only 100 μg were injected per mouse. All samples were set to have equal amounts of smURFP before injection. For subcutaneous injections, mice were monitored before and after injection at 1 h, 4 h, and 8 h. These experiments were repeated with different mice for the IV injections, except time points were taken before and after injection at 30 min, 1 h, and 2 h and the mice were sacrificed at 2 h.

Radiance efficiency calculation via ex vivo fluorescence imaging. Intravenously injected BALB/c mice were sacrificed after 2 h of systematic smURFP and S@VLPs administration. Organs were harvested and imaged under an IVIS Lumina III at an excitation of 620 nm and emission at 670 nm with a set exposure time of 2 s. Regions of interest were constructed for each organ imaged. Average fluorescence for each organ tested (n=3) was used for construction of a comparison plot between each of the samples injected. Mice injected with PBS were used as the control. In a similar

experiment, mice were injected intravenously with $S@Q\beta$ and S@PP7 (100 μg) and biodistribution recorded for 16 h. Mice were then sacrificed, major organs extracted, and their fluorescence intensity recorded.

Results and Discussion

Both $Q\beta$ and PP7 are highly functionalizable, monodisperse, biocompatible, and biodegradable icosahedral VLPs that range between 26 to 28 nm and are composed of 180 identical coat proteins. 48-49 These building units self-assemble around the negative charge of single stranded RNA and are joined together through disulfide bonds formed between pairs of surface exposed cysteines present in each coat protein. Control over the self-assembly properties of these VLPs can be exploited for the encapsulation of foreign material within their hollow capsid, 50-51 though, to our knowledge, this self-assembly has not been exploited to form fully proteinaceous near-IR imaging agents.




Figure 1. Characterization of smURFP@VLPs. A) Photograph of VLP samples irradiated by handheld UV lamp (350 nm) before and after encapsulation of smURFP. B) DLS of unmodified (native) and fluorescent VLPs. C) TEM micrographs of S@Qβ and D) S@PP7. Scale bar=100 nm.

Supramolecular encapsulation of smURFP within the hollow interior of the VLPs is straightforward and carried out via disassembly of the capsids upon incubation in a reducing solution—to reduce the 180 disulfides on either capsid—and at low pH and high salt concentration. Particle reassembly is achieved through incubation of the concentrated VLP monomers in the presence of ten-fold molar excess of smURFP at neutral pH. smURFP protein production is very straight forward and can be expressed in large (gram) quantities in the laboratory, ³⁸ thus permitting a stoichiometric excess during its use as a template. The whole synthesis is relatively efficient, and we were able to obtain a ~65% yield of S@VLP after

purification. The purified blue suspension exhibited red emission under UV light (Figure 1A) and show a uniform size distribution with comparable sizes to native and fluorescent VLPs by dynamic light scattering (DLS) (Figure 1B). Reassembly and morphology of the capsids was further confirmed by transmission electron microscopy (TEM) (Figure 1C and D), which showed no changes in the morphology between fluorescent and native VLPs (TEM micrographs of native Q β and PP7 are found in SI Figure S1A and S1B). From this, we conclude that the disassembly-reassembly approach does not result in any alteration or morphological changes of the proteinaceous nanocarriers used for our study.




Figure 2. Chromatography and gel electrophoresis characterization of S@VLPs. A) FPLC elution volumes of native Qβ, S@Qβ, and native smURFP (S(n)). Solid lines were recorded at 280 nm and dotted lines were recorded at 640 nm. B) FPLC elution volumes of native PP7, S@PP7, and S (n). Solid lines were recorded at 280 nm and dotted lines were recorded at 640 nm. C) Agarose of fluorescent VLPs, native capsids, and native smURFP. Top gel stained in blue shows protein bands imaged under Coomassie Brilliant Blue

To examine the fluorophore intactness of the as-synthetized fluorescent VLPs, ultraviolet-visible (UV/VIS) and fluorescence spectroscopy were performed. As expected, long-wavelength absorption with λ_{max} of 642 nm and fluorescence emission λ_{max} of 670 nm between native and encapsulated smURFP display identical spectral properties (Figure S1C and S1D). To verify smURFP encapsulation within the capsids. FPLC and gel electrophoresis were performed and compared to the respective native analogs (Figure 2). Overlapping absorbance recorded at 280 and 642 nm reveals the presence of smURFP within the capsids of both Qβ and PP7 (Figure 2A and B), which elute very early (12 mL) on our column. Native smURFP elutes later (20 mL), and samples of S@VLP contained no free smURFP per FPLC, confirming no particle leakage from within the capsids. Agarose electrophoretic mobility exhibits similar band positions between native and fluorescent VLPs when stained with Coomassie Brilliant Blue. Fluorescence gel imaging in the Cy5 channel shows only S@Qβ and S@PP7 bands with shifts matching the mobility 2C). Non-reducing SDSserved with Coomassie (Figure PAGE confirms the previous results, which shows the fluorescent proteins. Because the CP of both VLPs and smURFP are

approximately 15 kDa the bands appear to have similar electrophoretic mobilities by SDS PAGE (Figure 2D). smURFP is also known to form higher order aggregates, ⁵² which are also visible; however, fluorescence gel imaging in the Cy5 channel reveals signal only from monomeric smURFP.

Gel densitometry was used to quantify the concentration of smURFP present in both Q β and PP7 capsids. 10% non-reducing SDS PAGE was used to highlight the protein band pertaining to either the monomer unit of the VLP or smURFP. Varying concentrations of native smURFP and native Q β or PP7 were run in tandem with S@Q β and S@PP7 (Figure S2). Standard curves made from the protein band absorbances were constructed. From these data we conclude that there are approximately three smURFP per VLP, a result that is in line with literature⁴⁵ that used a similar templating strategy to capture GFP inside MS2.




Figure 3. pH responsive studies and live-cell imaging characterization of smURFP and GFP@VLPs. A) Emission spectra of smURFP@VLPs and native smURFP, obtained at λ_{max} 670 nm under varying pH values. B) Emission spectra of GFP@VLPs and native GFP, obtained at λ_{max} 509 nm at varying pH values. C) S@PP7 incubated in RAW 264.7 macrophages (4 h). Color code: blue, DAPI; red, Cy5. D) S@Qβ incubated in RAW 264.7 macrophages (4 h). Color code: blue, DAPI; red, Cy5. E) G@PP7 incubated in RAW 264.7 macrophages (4 h). Color code: blue, DAPI; green, GFP. F) G@Qβ incubated in RAW 264.7 macrophages (4 h). Color code: blue, DAPI; green, GFP. Scale bar= 20 μm.

Early elegant work³⁰ that produced GFP encapsulated Q β using a different approach placed an RNA aptamer and a Q β packing hairpin on Q β CPs, which facilitated the interaction of Rev peptide tagged GFP during VLP self-assembly. While the probe behaved well generally, and we have published using this exact construct in




Figure 4. A) Subcutaneous diffusion assay shows S@VLP formulations reside in the tissue longer than native smURRP, which is completely gone within 4 h. B) Plot of fluorescence radiance of the subcutaneous injection. As expected, saline, PP7 (n) and Q β (n) do not show any fluorescence. C) Intravenous administration of PBS as a negative control, S (n), S@Q β , and S@PP7 shows accumulation. Animals were imaged in the supine position show fluorescence kidneys and liver, *ex vivo* imaging of necropsied organs show localization in the liver for VLP but not S (n). D) Relative radiance at the time of sacrifice shows the principle location of accumulation is the liver and some in the kidney.

the past,6 we found live imaging difficult because of GFP's well known sensitivity to low pH.53 In particular, we found image living cells once the particles entered into late endosomes nearly impossible. smURFP, in contrast, has been shown to be relatively insensitive to pH, giving us hope that we could use this as a more pH independent system for live-cell imaging. Like GFP, the optical properties of smURFP align with the filter sets for Cv5, ubiquitous on modern imaging instruments. Before incubation in cells, we tested the stability of smURFP and S@VLPs against an array of pH values and compared them directly to GFP analogues. The recorded fluorescence intensity for smURFP, whether encapsulated or native, shows no quenching from pH 4-8 (Figure 3A). On the contrary, encapsulated and native GFP display significant quenching when incubated at pH 3-5 (Figure 3B), suggesting smURFP would be a better platform for in vitro imaging applications where the nanoparticle carriers would end up in the late endosomes and/or lysosomes.²⁸ To test this, a qualitative evaluation of VLP formulations prepared with GFP (G@VLP) and smURFP (S@VLP) were done via live-cell imaging. Fluorescent VLPs incubated with RAW-264.7 macrophages for 4 h show successful internalization for all systems. Importantly, data obtained from this study show that, at the same concentrations and identical laser powers, the smURFP containing VLPs were close to saturating the detector and clear puncta can be observed whereas the poorly resolved GFP analogue (Figure 3 C-F) are faintly visible in only some cells. These results are even more clear in the reconstructed Z-stacks (supporting information movies).

Next, we sought to test the *in vivo* performance of our new constructs. smURFP's optical properties lend it utility in near-infrared imaging through tissue. Recent work by Rodriguez and Ting³⁹ have shown that smURFP-BSA nanoparticles produce fluorescence bright enough to image tumors in live murine models. While it is

not the most red-shifted of the new ultra-red proteins, it is the brightest,³⁷ and we thus expected to visualize the probe in living animals following subcutaneous and intravenous injections.

First, we wanted to establish if the probe was visible under the skin at all. Prior to injection, the torso and limbs of the mice were shaved. Fluorescent samples were administered subcutaneously and monitored for 8 h (Figure 4A). We can also see that the capsids themselves show no fluorescence, even when imaged just under the skin, indicating that all fluorescence signal arises from the smURFP. The larger VLP formulations resided in the tissue for more than 4 h but had completely diffused from the area by 8 h. smURFP by itself, on the other hand, diffused from the injection site almost entirely at 4h (Figure 4B).

Next, we wanted to see if we could observe internal anatomy with our probe. Intravenous (tail vein) administration was likewise successful. We were able to distinguish both kidneys—the typical presentation of the right kidney positioned lower than the left—in depilated mice in the supine position after 120 minutes (**Figure 4C left**). *Ex vivo* imaging (**Figure 4C right**) confirms both kidneys and liver contained probe, with VLP formulations visible in the liver for as long as 16 hours post injection (**Figure S3**). Injections of smURFP protein, on the other hand, were apparent in very minute quantities in the liver at 2 h (Fig D).

Conclusion

Using a versatile supramolecular disassembly-reassembly approach, we have successfully encapsulated smURFP within the hollow capsids of two different VLPs— $Q\beta$ and PP7. The as-prepared fluorescent VLPs show size distributions and shapes consistent to their native analogs, as confirmed by DLS and TEM. Spectral properties between native and encapsulated smURFP were found to be

very similar. When compared to GFP loaded analogs, smURFP loaded VLPs are easier to image following phagocytosis in RAW macrophages, which we attribute to the better pH sensitivity of smURFP. Finally, smURFP encapsulated Q β and PP7 could be clearly visualized in the skin and mice and showed different tissue and organ localization compared to free smURFP. We believe these results will be helpful in developing new ways to non-invasively track VLPs based on these constructs in tissue in a myriad of biomedical applications.

Acknowledgements

We thank Professor M.G. Finn and Dr. Po-Yu Fang for their helpful discussion and insight as well as the gift of the plasmids. We also thank Professor Erik A Rodrigez for helpful discussions.

Funding

J. J. G. would like to thank the National Science Foundation [CAREER DMR-1654405] and the Welch Foundation [AT-1989-20190330]. C. E. B. thanks the National Science Foundation Graduate Research Fellows Program (1746053)

*Corresponding Author's email: Gassensmith@utdallas.edu;

Author Contributions

Primary manuscript writing and editing was done by Fabian C. Herbert, Olivia R. Brohlin, and Jeremiah J. Gassensmith. Gel electrophoresis, SEC, DLS, UV-Vis, mouse injections, and $ex\ vivo$ were done by Fabian C. Herbert. Live-cell imaging and SEM were done by Olivia R. Brohlin. Production of fluorescent VLPs was done by Tyler Galbraith. Expression and purification of smURFP and GFP was done by Candace E. Benjamin. Expression and purification of Q β and PP7 was done by Cesar A. Reyes. Mouse preparation prior to $in\ vivo$ studies was performed by Michael A. Luzuriaga. Fluorescence spectroscopy was performed by Arezoo Shahrivarkevishahi. Funding was raised by Jeremiah J. Gassensmith.

References

- 1. Chen, Z.; Li, N.; Li, S.; Dharmarwardana, M.; Schlimme, A.; Gassensmith, J. J., Viral chemistry: The Chemical Functionalization of Viral Architectures to Create New Technology. *Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol.* **2016**, *8* (4), 512-534.
- 2. Dharmarwardana, M.; Martins, A. F.; Chen, Z.; Palacios, P. M.; Nowak, C. M.; Welch, R. P.; Li, S.; Luzuriaga, M. A.; Bleris, L.; Pierce, B. S.; Sherry, A. D.; Gassensmith, J. J., Nitroxyl Modified Tobacco Mosaic Virus as a Metal-free High-Relaxivity MRI and EPR Active Superoxide Sensor. *Mol. Pharmaceutics* **2018**, *15* (8), 2973-2983.
- 3. Lee, H.; Shahrivarkevishahi, A.; Lumata, J. L.; Luzuriaga, M. A.; Hagge, L. M.; Benjamin, C. E.; Brohlin, O. R.; Parish, C. R.; Firouzi, H. R.; Nielsen, S. O.; Lumata, L. L.; Gassensmith, J. J., Supramolecular and Biomacromolecular Enhancement of Metal-free Magnetic Resonance Imaging Contrast Agents. *Chem. Sci.* **2020**, *11* (8), 2045-2050.
- 4. Chen, Z.; Li, N.; Chen, L.; Lee, J.; Gassensmith, J. J., Dual Functionalized Bacteriophage Qbeta as a Photocaged Drug Carrier. *Small* **2016**, *12* (33), 4563-4571.
- 5. Welch, R. P.; Lee, H.; Luzuriaga, M. A.; Brohlin, O. R.; Gassensmith, J. J., Protein–Polymer Delivery: Chemistry from the Cold Chain to the Clinic. *Bioconjugate Chem.* **2018**, *29* (9), 2867-2883.
- 6. Lee, H.; Benjamin, C. E.; Nowak, C. M.; Tuong, L. H.; Welch, R. P.; Chen, Z.; Dharmarwardana, M.; Murray, K. W.; Bleris, L.; D'Arcy, S.; Gassensmith, J. J., Regulating the Uptake of Viral Nanoparticles in Macrophage and Cancer Cells via a pH Switch. *Mol. Pharmaceutics* **2018**, *15* (8), 2984-2990.

- 7. Benjamin, C. E.; Chen, Z.; Kang, P.; Wilson, B. A.; Li, N.; Nielsen, S. O.; Qin, Z.; Gassensmith, J. J., Site-Selective Nucleation and Size Control of Gold Nanoparticle Photothermal Antennae on the Pore Structures of a Virus. *J. Am. Chem. Soc.* **2018**, *140* (49), 17226-17233.
- 8. Aniagyei, S. E.; Dufort, C.; Kao, C. C.; Dragnea, B., Self-assembly Approaches to Nanomaterial Encapsulation in Viral Protein Cages. *J. Mater. Chem.* **2008**, *18* (32), 3763-3774.
- 9. Luzuriaga, M. A.; Welch, R. P.; Dharmarwardana, M.; Benjamin, C. E.; Li, S.; Shahrivarkevishahi, A.; Popal, S.; Tuong, L. H.; Creswell, C. T.; Gassensmith, J. J., Enhanced Stability and Controlled Delivery of MOF-Encapsulated Vaccines and Their Immunogenic Response In Vivo. *ACS Appl. Mater. Interfaces* **2019**, *11* (10), 9740-9746.
- 10. Murray, A. A.; Sheen, M. R.; Veliz, F. A.; Fiering, S. N.; Steinmetz, N. F., In Situ Vaccination of Tumors Using Plant Viral Nanoparticles. *Methods Mol. Biol.* **2019**, *2000*, 111-124.
- 11. Wang, C.; Beiss, V.; Steinmetz, N. F., Cowpea Mosaic Virus Nanoparticles and Empty Virus-Like Particles Show Distinct but Overlapping Immunostimulatory Properties. *J. Virol.* **2019**, *93* (21), e00129-19.
- 12. Li, S.; Dharmarwardana, M.; Welch, R. P.; Benjamin, C. E.; Shamir, A. M.; Nielsen, S. O.; Gassensmith, J. J., Investigation of Controlled Growth of Metal–Organic Frameworks on Anisotropic Virus Particles. ACS Appl. Mater. Interfaces 2018, 10 (21), 18161-18169.
- 13. Lee, P. W.; Shukla, S.; Wallat, J. D.; Danda, C.; Steinmetz, N. F.; Maia, J.; Pokorski, J. K., Biodegradable Viral Nanoparticle/Polymer Implants Prepared via Melt-Processing. *ACS Nano* **2017**, *11* (9), 8777-8789.
- 14. Rynda-Apple, A.; Patterson, D. P.; Douglas, T., Virus-Like Particles as Antigenic Nanomaterials for Inducing Protective Immune Responses in the Lung. *Nanomedicine* **2014**, *9* (12), 1857-1868.
- 15. Zhao, L.; Kopylov, M.; Potter, C. S.; Carragher, B.; Finn, M. G., Engineering the PP7 Virus Capsid as a Peptide Display Platform. *ACS Nano* **2019**, *13* (4), 4443-4454.
- 16. Liu, J.; Dai, S.; Wang, M.; Hu, Z.; Wang, H.; Deng, F., Virus Like Particle-Based Vaccines Against Emerging Infectious Disease Viruses. *Virol. Sin.* **2016**, *31* (4), 279-287.
- 17. Pokorski, J. K.; Hovlid, M. L.; Finn, M. G., Cell Targeting with Hybrid Qβ Virus-Like Particles Displaying Epidermal Growth Factor. *ChemBioChem* **2011**, *12* (16), 2441-2447.
- 18. Prasuhn, D. E., Jr.; Singh, P.; Strable, E.; Brown, S.; Manchester, M.; Finn, M. G., Plasma Clearance of Bacteriophage Qβ Particles as a Function of Surface Charge. *J. Am. Chem. Soc.* **2008**, *130* (4), 1328-1334.
- 19. Chen, Z.; Boyd, S. D.; Calvo, J. S.; Murray, K. W.; Mejia, G. L.; Benjamin, C. E.; Welch, R. P.; Winkler, D. D.; Meloni, G.; D'Arcy, S.; Gassensmith, J. J., Fluorescent Functionalization Across Quaternary Structure in a Virus-Like Particle. *Bioconjugate Chem.* **2017**, *28* (9), 2277-2283.
- 20. Dharmarwardana, M.; Martins, A. F.; Chen, Z.; Palacios, P. M.; Nowak, C. M.; Welch, R. P.; Li, S.; Luzuriaga, M. A.; Bleris, L.; Pierce, B. S.; Sherry, A. D.; Gassensmith, J. J., Nitroxyl Modified Tobacco Mosaic Virus as a Metal-Free High-Relaxivity MRI and EPR Active Superoxide Sensor. *Mol. Pharmaceutics* **2018**, *15* (8), 2973-2983.
- 21. Chen, C. C.; Stark, M.; Baikoghli, M.; Cheng, R. H., Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods. *J. Visualized Exp.* **2018**, *135*, e57020.
- 22. Sainsbury, F.; Saunders, K.; Aljabali, A. A.; Evans, D. J.; Lomonossoff, G. P., Peptide-controlled Access to the Interior Surface of Empty Virus Nanoparticles. *ChemBioChem* **2011**, *12* (16), 2435-2440.
- 23. Steinmetz, N. F., Viral Nanoparticles as Platforms for Next-generation Therapeutics and Imaging Devices. *Nanomedicine* **2010**, *6* (5), 634-641.
- 24. Nanduri, V.; Balasubramanian, S.; Sista, S.; Vodyanoy, V. J.; Simonian, A. L., Highly Sensitive Phage-based Biosensor for the Detection of Beta-galactosidase. *Anal. Chim. Acta* **2007**, *589* (2), 166-172.
- 25. Robertson, K. L.; Liu, J. L., Engineered Viral Nanoparticles for Flow Cytometry and Fluorescence Microscopy Applications. *Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.* **2012**, *4* (5), 511-524.
- Lewis, J. D.; Destito, G.; Zijlstra, A.; Gonzalez, M. J.; Quigley,
 J. P.; Manchester, M.; Stuhlmann, H., Viral nanoparticles as tools for intravital vascular imaging. *Nat. Med.* 2006, 12 (3), 354-360.
- 27. Carrico, Z. M.; Farkas, M. E.; Zhou, Y.; Hsiao, S. C.; Marks, J. D.; Chokhawala, H.; Clark, D. S.; Francis, M. B., N-Terminal Labeling of Filamentous Phage to Create Cancer Marker Imaging Agents. *ACS Nano* **2012**, *6* (8), 6675-6680.
- 28. Benjamin, C. E.; Chen, Z.; Brohlin, O.; Lee, H.; Boyd, S.; Winkler, D. D.; Gassensmith, J. J., Using FRET to Measure the Time it

- Takes for a Cell to Destroy a Virus. 2019, chemXiv: chemistry/10299164.

 ArXiv.org e-Print archive.

 http://chemRxiv.org/articles/Using Fret to Measure the Time it Takes for a Cell to Destroy a Virus/10299164 (accessed Mar 29, 2020).
- 29. Jaffe, J.; Wucherer, K.; Sperry, J.; Zou, Q.; Chang, Q.; Massa, M. A.; Bhattacharya, K.; Kumar, S.; Caparon, M.; Stead, D.; Wright, P.; Dirksen, A.; Francis, M. B., Effects of Conformational Changes in Peptide-CRM197 Conjugate Vaccines. *Bioconjugate Chem.* **2019**, *30* (1), 47-53.
- 30. Rhee, J. K.; Hovlid, M.; Fiedler, J. D.; Brown, S. D.; Manzenrieder, F.; Kitagishi, H.; Nycholat, C.; Paulson, J. C.; Finn, M. G., Colorful Virus-like Particles: Fluorescent Protein Packaging by the Qbeta capsid. *Biomacromolecules* **2011**, *12* (11), 3977-3981.
- 31. Minten, I. J.; Claessen, V. I.; Blank, K.; Rowan, A. E.; Nolte, R. J. M.; Cornelissen, J. J. L. M., Catalytic Capsids: The Art of Confinement. *Chem. Sci.* **2011**, *2* (2), 358-362.
- 32. Luker, K. E.; Pata, P.; Shemiakina, II; Pereverzeva, A.; Stacer, A. C.; Shcherbo, D. S.; Pletnev, V. Z.; Skolnaja, M.; Lukyanov, K. A.; Luker, G. D.; Pata, I.; Chudakov, D. M., Comparative Study Reveals Better Far-red Fluorescent Protein for Whole Body Imaging. *Sci. Rep.* **2015**, *5*, 10332
- 33. Smith, A. M.; Mancini, M. C.; Nie, S., Bioimaging: Second Window for *in vivo* Imaging. *Nat. Nanotechnol.* **2009**, *4* (11), 710-711.
- 34. Shcherbakova, D. M.; Subach, O. M.; Verkhusha, V. V., Red Fluorescent Proteins: Advanced Imaging Applications and Future Design. *Angew. Chem. Int. Ed. Engl.* **2012**, *51* (43), 10724-10738.
- 35. Morozova, K. S.; Piatkevich, K. D.; Gould, T. J.; Zhang, J.; Bewersdorf, J.; Verkhusha, V. V., Far-red Fluorescent Protein Excitable with Red Lasers for Flow Cytometry and Superresolution STED Nanoscopy. *Biophys. J.* **2010**, *99* (2), L13-5.
- 36. Wang, L.; Jackson, W. C.; Steinbach, P. A.; Tsien, R. Y., Evolution of New Nonantibody Proteins via Iterative Somatic Hypermutation. *Proc. Natl. Acad. Sci. U. S. A.* **2004**, *101* (48), 16745-16749.
- 37. Rodriguez, E. A.; Tran, G. N.; Gross, L. A.; Crisp, J. L.; Shu, X.; Lin, J. Y.; Tsien, R. Y., A Far-red Fluorescent Protein Evolved from a Cyanobacterial Phycobiliprotein. *Nat. Methods* **2016**, *13* (9), 763-769.
- 38. Oliinyk, O. S.; Chernov, K. G.; Verkhusha, V. V., Bacterial Phytochromes, Cyanobacteriochromes and Allophycocyanins as a Source of Near-Infrared Fluorescent Probes. *Int. J. Mol. Sci.* **2017**, *18* (8), 1691.
- 39. An, F.; Chen, N.; Conlon, W. J.; Hachey, J. S.; Xin, J.; Aras, O.; Rodriguez, E. A.; Ting, R., Small Ultra-red Fluorescent Protein Nanoparticles as Exogenous Probes for Noninvasive Tumor Imaging In Vivo. *Int. J. Biol. Macromol.* **2020**, *153*, 100-106.
- 40. Shaner, N. C.; Campbell, R. E.; Steinbach, P. A.; Giepmans, B. N.; Palmer, A. E.; Tsien, R. Y., Improved Monomeric Red, Orange and Yellow Fluorescent Proteins Derived from Discosoma Sp. Red Fluorescent Protein. *Nat. Biotechnol.* **2004**, *22* (12), 1567-1572.
- 41. Kredel, S.; Nienhaus, K.; Oswald, F.; Wolff, M.; Ivanchenko, S.; Cymer, F.; Jeromin, A.; Michel, F. J.; Spindler, K. D.; Heilker, R.;

- Nienhaus, G. U.; Wiedenmann, J., Optimized and Far-red-emitting Variants of Fluorescent Protein eqFP611. *Chem. Biol.* **2008**, *15* (3), 224-233.
- 42. Shcherbo, D.; Merzlyak, E. M.; Chepurnykh, T. V.; Fradkov, A. F.; Ermakova, G. V.; Solovieva, E. A.; Lukyanov, K. A.; Bogdanova, E. A.; Zaraisky, A. G.; Lukyanov, S.; Chudakov, D. M., Bright Far-red Fluorescent Protein for Whole-body Imaging. *Nat. Methods* **2007**, *4* (9), 741-746
- 43. Oliinyk, O. S.; Shemetov, A. A.; Pletnev, S.; Shcherbakova, D. M.; Verkhusha, V. V., Smallest Near-infrared Fluorescent Protein Evolved from Cyanobacteriochrome as Versatile Tag for Spectral Multiplexing. *Nat. Comm.* **2019**, *10* (1), 279.
- 44. Capehart, S. L.; Coyle, M. P.; Glasgow, J. E.; Francis, M. B., Controlled Integration of Gold Nanoparticles and Organic Fluorophores Using Synthetically Modified MS2 Viral Capsids. *J. Am. Chem. Soc.* **2013**, *135* (8), 3011-3016.
- Glasgow, J. E.; Capehart, S. L.; Francis, M. B.; Tullman-Ercek,
 D., Osmolyte-mediated Encapsulation of Proteins Inside MS2 Viral Capsids. ACS Nano 2012, 6 (10), 8658-8664.
- 46. Gysi, J. R.; Zuber, H., Properties of Allophycocyanin II and its Alpha- and Beta-subunits from the Thermophilic Blue--green Alga Mastigocladus Laminosus. *Biochem. J.* **1979**, *181* (3), 577-583.
- 47. Chen, Z.; Detvo, S. T.; Pham, E.; Gassensmith, J. J., Making Conjugation-induced Fluorescent PEGylated Virus-like Particles by Dibromomaleimide-disulfide Chemistry. *J. Visualized Exp.* **2018**, (135), e57712.
- 48. Koudelka, K. J.; Pitek, A. S.; Manchester, M.; Steinmetz, N. F., Virus-Based Nanoparticles as Versatile Nanomachines. *Annu. Rev. Virol.* **2015**, *2* (1), 379-401.
- 49. Schwarz, B.; Uchida, M.; Douglas, T., Biomedical and Catalytic Opportunities of Virus-Like Particles in Nanotechnology. *Adv. Virus Res.* **2017**, *97*, 1-60.
- 50. Sun, J.; DuFort, C.; Daniel, M.-C.; Murali, A.; Chen, C.; Gopinath, K.; Stein, B.; De, M.; Rotello, V. M.; Holzenburg, A.; Kao, C. C.; Dragnea, B., Core-controlled Polymorphism in Virus-like Particles. *Proc. Natl. Acad. Sci. U. S.A.* **2007**, *104* (4), 1354-1359.
- 51. Liu, A.; de Ruiter, M. V.; Zhu, W.; Maassen, S. J.; Yang, L.; Cornelissen, J. J. L. M., Compartmentalized Thin Films with Customized Functionality via Interfacial Cross-linking of Protein Cages. *Adv. Func. Mater.* **2018**, *28* (34), 1801574.
- 52. Ding, W. L.; Miao, D.; Hou, Y. N.; Jiang, S. P.; Zhao, B. Q.; Zhou, M.; Scheer, H.; Zhao, K. H., Small Monomeric and Highly Stable Near-infrared Fluorescent Markers Derived from the Thermophilic Phycobiliprotein, ApcF2. *Biochim. Biophys. Acta, Mol. Cell Res.* **2017**, *1864* (10), 1877-1886.
- 53. Kneen, M.; Farinas, J.; Li, Y.; Verkman, A. S., Green Fluorescent Protein as a Noninvasive Intracellular pH Indicator. *Biophys. J.* **1998**, *74* (3), 1591-1599.

Supporting Information

Supramolecular Encapsulation of Small-Ultra Red Fluorescent Proteins in Virus-Like Nanoparticles for Non-Invasive In Vivo Imaging Agents

Fabian C. Herbert,† Olivia R. Brohlin,† Tyler Galbraith,† Candace Benjamin,† Cesar A. Reyes,† Michael A. Luzuriaga,† Arezoo Shahrivarkevishahi,† and Jeremiah J. Gassensmith*,†,‡

†Department of Chemistry and Biochemistry, ‡Department of Bioengineering, The University of Texas at Dallas, 800 West Campbell Road, Richardson, TX 75080, USA

Instrumentation.

Dynamic-light scattering

Samples were measured using UV-Vis Malvern Panalytical Zetasizer Nano ZS. Each sample was loaded in a disposable microcuvette, measured at 25 °C with a 633 nm laser, 175° scattering angle, material refractive index of 1.51, and medium refractive index of 1.33.

UV-Vis

UV-Vis characterization was done using a Shimadzu UV-1601 PC UV-Vis-NIR Spectrophotometer using a 1.5 mL disposable cuvette. Sample concentrations were determined using a Biotek Synergy H4 hybrid reader or a Thermo Scientific NanoDrop 2000 Spectrophotometer.

Fluorescence Spectrophotometer

Measurements were performed using a Biotek Synergy H4 hybrid reader.

TEM

Transmission electron microscopy (TEM) was performed on a JEOL JEM-1400plus transmission electron microscope. Samples were prepared by incubating 5 μ L of a 40 nM sample solution on a 300 mesh formvar-coated copper grid with 5 μ L of 2% uranyl acetate for 60 s. Excess liquid was wicked away with Whatman (#1) filter paper before letting the grid dry in air. Images were taken with an accelerating voltage of 120 kV.

Gel Electrophoresis

1% agarose gels were run at 100 V for 30 mins with 1 × TBE running buffer. Samples were prepared in 100% glycerol. 10% SDS PAGE gels were run at 150 V for 75 min with SDS running buffer. Samples were prepared in SDS loading dye and ran using a Fisher BioReagents EZ-Run Prestained protein marker. Gels were first imaged by Biomolecular Imager-GE Typhoon FLA 9000 for Cy5 fluorescence. After, the gels were stained with Coomassie Brilliant Blue and imaged by BioRad ChemiDoc Gel Imager.

In vivo Fluorescence Imager

Fluorescent animal imaging was taken with IVIS Lumina III (PerkinElmer, Waltham, MA, USA) at an excitation of 620 nm and emission at 670 nm with a 5 s exposure.

Supplementary Figures.




Figure S1 Native capsid characterization and spectral properties of fluorescent VLPs. A) TEM micrographs of Q β and B) PP7. C) UV-Vis spectra of native and encapsulated smURFP. D) Emission spectra at λ_{max} 642 nm of native and encapsulated smURFP.




Figure S2. Quantification of smURFP proteins per VLP capsid. A) UV-Vis standard curve used for concentration determination of smURFP present in Q β and PP7. B) 10% non-reducing SDS PAGE of native smURFP, native Q β , and S@Q β . C) 10% non-reduced SDS PAGE of native smURFP, native PP7, and S@PP7.





Figure S3. *Ex vivo* of intravenously injected S@VLPs. Organs extracted at 16 h time-point from mice injected intravenously with S@VLPs.



graphical abstract.png (391.06 KiB)

view on ChemRxiv • download file